bronchiol
commonest
caus
hospit
admiss
infanc
sever
vari
mild
selflimit
respiratori
failur
requir
intens
care
ventil
mani
virus
caus
bronchiol
commonest
respiratori
syncyti
viru
rsv
support
care
mainstay
treatment
emphasi
fluid
replac
oxygen
therapi
agent
evid
benefit
acut
bronchiol
includ
agonist
ipratropium
montelukast
corticosteroid
antivir
agent
ribavirin
rsv
immunoglobulin
physiotherapi
nebul
deoxyribonucleas
antibiot
possibl
nebul
epinephrin
small
shortterm
effect
nebul
hyperton
salin
administ
bronchodil
may
decreas
length
stay
hospit
prevent
strategi
rsv
immunoglobulin
antirsv
monoclon
antibodi
palivizumab
decreas
diseas
sever
eor
reynold
conclud
oxygen
therapi
vital
import
bronchiol
littl
convinc
evid
therapi
consist
even
occasion
use
arguabl
littl
progress
subsequ
year
treatment
might
effect
includ
nebul
hyperton
salin
mix
bronchodil
ventilatori
support
respiratori
failur
major
patient
howev
support
manag
mainstay
emphasi
treat
insuffici
fluid
intak
hypoxia
bronchiol
commonest
caus
hospit
infanc
usual
affect
infant
age
month
although
occur
year
age
usual
mild
selflimit
ill
requir
medic
intervent
clinic
syndrom
character
initi
coryz
symptom
follow
madelein
adam
mrcpch
onset
harsh
cough
tachypnoea
wheez
examin
may
chest
hyperinfl
costal
recess
fine
inspiratori
crackl
polyphon
expiratori
wheez
auscult
signific
contributor
confus
manag
bronchiol
absenc
intern
agre
common
definit
unit
kingdom
australasia
part
europ
bronchiol
interpret
presenc
tachypnoea
hyperinfl
chest
characterist
widespread
fine
end
inspiratori
crackl
auscult
wheez
commonli
invari
present
pattern
ill
virtual
alway
seen
first
year
life
commonli
first
month
life
contrast
north
america
part
europ
bronchiol
term
viral
infect
lower
respiratori
tract
first
year
life
may
includ
children
recurr
wheez
confus
definit
compound
differ
type
studi
mani
studi
inpati
closer
uk
australasian
definit
mani
studi
outpati
includ
mostli
children
correspond
north
american
european
definit
furthermor
wide
accept
valid
score
system
measur
ill
sever
make
comparison
studi
difficult
commonli
outcom
measur
intervent
studi
includ
summat
score
symptom
sign
oxygen
satur
respiratori
rate
length
stay
hospit
approxim
infant
hospit
bronchiol
requir
ventil
either
respiratori
failur
apnoea
hospit
bronchiol
common
boy
lower
socioeconom
group
preterm
infant
less
week
infant
chronic
lung
diseas
congenit
cardiac
abnorm
immun
defici
higher
risk
sever
diseas
mortal
rate
hospit
infant
respiratori
syncyti
viru
rsv
account
case
bronchiol
result
approxim
uk
admiss
per
year
annual
epidem
rsv
occur
late
autumn
spring
octob
march
northern
hemispher
viru
rapidli
infect
respiratori
tract
epithelium
caus
epitheli
necrosi
destruct
cilia
florid
inflammatori
respons
neutrophil
lymphocyt
cellular
infiltr
oedema
submucosa
imbal
cytokin
excess
th
type
ii
type
cytokin
demonstr
high
interleukin
interferon
ratio
increas
mucu
product
goblet
cell
combin
decim
epitheli
cell
result
mucu
plug
mucu
plug
caus
obstruct
bronchiol
result
air
trap
lead
area
hyperinfl
airway
collaps
respiratori
epithelium
regener
new
noncili
cell
poorli
equip
clear
inflammatori
debri
hypoxaemia
primarili
due
ventilationperfus
mismatch
hypercapnoea
rel
late
phenomenon
rsv
next
frequent
caus
probabl
human
metapneumoviru
hmpv
caus
similar
clinic
pictur
rsv
although
dual
infect
rsv
hmpv
may
caus
sever
diseas
rhinoviru
may
common
caus
older
infant
less
frequent
caus
includ
adenoviru
parainfluenza
influenza
coronaviru
recent
identifi
bocaviru
possibl
bacteri
superinfect
associ
increas
sever
diseas
intervent
class
support
therapeut
prevent
current
manag
bronchiol
primarili
support
concentr
major
effect
condit
name
inadequ
feed
respiratori
distress
apnoea
inadequ
feed
usual
secondari
respiratori
distress
consequ
increas
work
breath
infant
tachypno
may
bout
cough
increas
upper
airway
secret
thu
may
struggl
feed
adequ
tachypnoea
increas
fluid
loss
infant
easili
becom
dehydr
infant
bronchiol
gener
intoler
intervent
minim
handl
recommend
milder
case
give
small
volum
feed
regular
interv
may
suffici
administr
oxygen
may
enough
decreas
work
breath
allow
regular
fluid
intak
prove
inadequ
nasogastr
tube
pass
administ
enter
fluid
initi
bolu
feed
worsen
respiratori
distress
continu
feed
ultim
infant
unabl
toler
enter
feed
fluid
administ
intraven
rsv
infect
result
inappropri
syndrom
inappropri
antidiuret
hormon
secret
siadh
determin
serum
electrolyt
intraven
fluid
usual
restrict
mainten
requir
ventilationperfus
mismatch
characterist
bronchiol
result
hypoxia
increas
work
breath
oxygen
mainstay
treatment
respiratori
distress
usual
administ
via
headbox
minim
handl
higher
concentr
combin
head
box
facemask
rebreath
bag
may
use
although
usual
impli
signific
respiratori
failur
often
preced
respiratori
collaps
increas
impair
ga
exchang
result
hypoxia
unrespons
headbox
oxygen
hypercarbia
eventu
lead
physic
exhaust
complet
respiratori
failur
bronchiol
admiss
respiratori
failur
increasingli
noninvas
ventil
use
offer
continu
posit
airway
pressur
cpap
support
usual
via
nasal
prong
decreas
need
intub
sedat
thought
action
cpap
prevent
airway
collaps
respiratori
cycl
preserv
ventil
decreas
ventilationperfus
mismatch
observ
studi
suggest
bronchiol
cpap
decreas
respiratori
rate
puls
rate
partial
pressur
carbon
dioxid
decreas
intub
rate
consequ
rate
ventilatorassoci
pneumonia
cpap
appear
affect
length
hospit
stay
durat
ventil
control
studi
demonstr
initi
earli
nasal
cpap
result
signific
decreas
pco
well
toler
without
signific
complic
suggest
earlier
intervent
would
improv
outcom
respiratori
failur
continu
despit
nasal
cpap
full
intub
ventil
warrant
mechan
ventil
administr
exogen
surfact
may
decreas
durat
mechan
ventil
mechan
ventil
ineffect
may
role
extracorpor
membran
oxygen
ecmo
interpret
evid
efficaci
bronchodil
bronchiol
hamper
heterogen
inclus
criteria
differ
studi
mani
studi
particularli
outpatientbas
includ
infant
year
old
recurr
wheez
arguabl
mani
infant
may
asthma
phenotyp
three
class
bronchodil
triall
bronchiol
agonist
ipratropium
adrenerg
agent
shown
benefit
asthmat
bronchodil
treatment
choic
acut
asthma
older
children
adult
evid
bronchodil
may
produc
shortterm
improv
clinic
score
outpatientbas
studi
bronchiol
earlier
metaanalysi
flore
horwitz
conclud
agonist
statist
signific
clinic
insignific
effect
oxygen
satur
heart
rate
use
milder
case
outpati
set
signific
effect
hospit
later
systemat
review
pharmacolog
treatment
conclud
agonist
signific
benefici
effect
recent
cochran
review
trial
involv
infant
bronchiol
receiv
inhal
bronchodil
includ
agonist
ipratropium
adrenerg
agent
report
signific
improv
overal
averag
clinic
score
effect
either
puls
oximetri
measur
risk
hospit
howev
inclus
criteria
mani
studi
allow
children
recurr
wheez
month
age
subgroup
analysi
suggest
benefit
primarili
outpati
studi
shorter
durat
suggest
mani
show
benefit
may
recurr
wheez
rather
isol
bronchiol
earlier
systemat
review
identifi
four
studi
assess
use
nebul
ipratropium
bromid
bronchiol
conclud
signific
benefit
subsequ
cochran
analysi
reach
similar
conclus
like
ipratropium
role
young
infant
recurr
wheez
adrenerg
agent
epinephrin
appear
attract
combin
effect
bronchodil
effect
vasoconstrict
bronchiolar
vasculatur
vasoconstrict
action
particular
could
potenti
decreas
characterist
mucos
oedema
mucu
hypersecret
metaanalysi
studi
conclud
nebul
epinephrin
benefici
effect
compar
either
placebo
salbutamol
effect
shortterm
studi
inpati
compar
placebo
epinephrin
result
significantli
better
clinic
score
minut
compar
salbutamol
result
significantli
lower
respiratori
rate
minut
shortterm
benefit
pronounc
outpati
studi
benefit
last
less
minut
effect
hospit
rate
thu
summari
littl
evid
benefit
bronchodil
bronchiol
evid
shortterm
benefit
epinephrin
mostli
outpati
set
may
reflect
benefit
infant
recurr
wheez
phenotyp
leukotrien
receptor
antagonist
montelukast
may
benefici
young
children
infant
start
earli
acut
mostli
virusinduc
asthmawheez
howev
recent
placebocontrol
studi
montelukast
infant
first
episod
bronchiol
demonstr
absenc
benefit
signific
differ
length
hospit
clinic
sever
score
inflammatori
mediat
two
group
corticosteroid
would
appear
attract
therapi
bronchiol
bronchiol
character
florid
inflammatori
respons
antiinflammatori
action
corticosteroid
benefici
older
children
adult
asthma
unfortun
larg
bodi
evid
lack
benefit
bronchiol
recent
cochran
review
trial
includ
nearli
children
age
month
receiv
equival
mgkg
system
prednison
day
although
length
hospit
day
shorter
steroidtr
group
differ
signific
similar
lack
signific
differ
respiratori
rate
oxygen
satur
need
supplement
oxygen
need
support
fluid
need
bronchodil
furthermor
corticosteroid
show
signific
benefit
even
subgroup
analys
infant
less
month
age
confirm
respiratori
syncyti
viru
rsv
infect
previou
histori
wheez
interest
note
recent
larg
trial
oral
corticosteroid
older
preschool
children
acut
wheez
also
demonstr
benefit
mode
action
hyperton
salin
hs
bronchiol
unclear
vitro
hs
increas
airway
surfac
liquid
asl
height
epitheli
cell
line
model
vivo
hs
increas
mucociliari
clearanc
radiolabel
aerosol
normal
control
asthmat
hyperton
salin
increasingli
util
cystic
fibrosi
cf
increas
mucociliari
clearanc
least
hour
dosedepend
manner
increas
sputum
expector
random
placebocontrol
studi
ml
hs
administ
twice
daili
via
nebul
result
signific
decreas
number
mild
sever
respiratori
exacerb
day
antibiot
receiv
per
year
number
day
absent
work
school
hs
induc
bronchospasm
even
normal
adult
cf
recommend
hs
administ
bronchodil
increas
evid
diseas
pathogenesi
cf
due
increas
sodium
absorpt
airway
surfac
lead
airway
dehydr
subsequ
loss
normal
asl
volum
thu
decreas
ciliari
clearanc
administr
hs
thought
attract
water
airway
increas
asl
volum
ciliari
clearanc
agent
attract
water
airway
sugar
alcohol
mannitol
similar
effect
unclear
whether
similar
mode
action
applic
bronchiol
postul
mode
action
includ
breakdown
ionic
bond
within
airway
mucu
result
decreas
mucu
viscos
eas
clearanc
airway
secret
increas
prostaglandin
e
releas
stimul
ciliari
beat
frequenc
possibl
hs
simpli
induc
cough
even
normal
subject
action
could
simpli
tussiv
effect
cochran
review
four
trial
hs
infant
bronchiol
demonstr
significantli
decreas
durat
hospit
three
trial
group
investig
use
similar
treatment
protocol
administ
ml
hs
everi
hour
mix
either
mg
epinephrin
mg
terbutalin
although
administr
bronchodil
essenti
trial
major
subject
concomitantli
receiv
bronchodil
pool
data
suggest
hs
decreas
median
durat
stay
day
confid
interv
p
compar
nebul
salin
although
signific
effect
hospit
rate
control
trial
antivir
agent
ribavirin
via
aerosol
infant
receiv
mechan
ventil
sever
rsv
infect
initi
show
signific
benefit
although
concern
choic
aerosol
water
control
repeat
studi
use
aerosol
salin
control
demonstr
benefit
subsequ
metaanalysi
control
trial
conclud
signific
benefit
aerosol
ribavirin
although
may
slight
reduct
durat
mechan
ventil
may
howev
role
intraven
ribavirin
sever
diseas
immunocompromis
patient
intraven
rsv
immun
globulin
ineffect
acut
treatment
rsv
lower
respiratori
tract
infect
treatment
shown
benefit
acut
bronchiol
includ
nebul
deoxyribonucleas
chest
physiotherapi
antibiot
infant
known
risk
sever
bronchiol
receiv
passiv
immun
rsv
either
rsv
immunoglobulin
rsvig
monthli
intraven
inject
monthli
intramuscular
inject
human
monoclon
antibodi
palivizumab
neither
risk
rsv
transmiss
neither
interfer
routin
childhood
vaccin
schedul
prevent
studi
random
doubleblind
comparison
rsv
immunoglobulin
prophylaxi
everi
day
versu
placebo
prematur
infant
infant
bronchopulmonari
dysplasia
demonstr
signific
reduct
hospit
rsv
durat
hospit
demonstr
signific
effect
need
mechan
ventil
day
intens
care
mortal
rsvig
longer
use
need
monthli
intraven
infus
small
theoret
risk
viral
transmiss
probabl
agent
divid
neonatologist
respiratori
paediatrician
much
palivizumab
palivizumab
human
immunoglobulin
bind
rsv
fusion
protein
cotton
rat
model
potent
rsv
immunoglobulin
prevent
entri
rsv
cell
line
respiratori
tract
administ
intramuscularli
half
life
day
administ
monthli
intramuscular
inject
rsv
season
current
licens
use
preterm
infant
less
week
gestat
less
month
old
start
bronchiol
season
child
year
age
receiv
treatment
bronchopulmonari
dysplasia
previou
month
children
haemodynam
signific
heart
diseas
impact
studi
placebocontrol
trial
intramuscular
palivizumab
everi
day
highrisk
infant
infant
either
born
earlier
week
gestat
less
month
age
less
year
age
clinic
diagnosi
bronchopulmonari
dysplasia
requir
treatment
oxygen
corticosteroid
bronchodil
diuret
preced
month
palivizumab
significantli
decreas
risk
hospit
durat
hospit
need
intens
care
although
signific
effect
either
need
ventil
death
although
rel
effect
strike
absolut
effect
much
less
calcul
number
need
treat
nnt
due
high
cost
econom
valu
question
estim
cost
prevent
one
hospit
admiss
joint
committe
vaccin
immun
jcvi
recommend
palivuzimab
given
children
less
year
age
previous
treat
home
oxygen
chronic
lung
diseas
haemodynam
signific
congenit
heart
diseas
pulmonari
hypertens
sever
congenit
immun
defici
despit
recommend
use
palivuzimab
vari
greatli
differ
area
uk
present
effect
vaccin
bronchiol
attempt
made
develop
vaccin
rsv
howev
vaccin
enter
clinic
trial
patient
given
vaccin
went
develop
sever
symptom
vaccin
current
effort
develop
vaccin
suitabl
human
trial
focu
use
nonanimalderiv
materi
obtain
viral
plasmid
dna
present
effici
viral
recoveri
fluid
oxygen
mainstay
manag
increas
evid
role
nebul
hyperton
salin
administ
bronchodil
cpap
necessari
mechan
ventil
effect
respiratori
failur
palivizumab
decreas
risk
hospit
highrisk
infant
although
controversi
benefit
wheez
chest
hyperinfl
costal
recess
examin
fine
inspiratori
crackl
polyphon
expiratori
wheez
auscult
rsv
account
case
bronchiol
caus
agent
includ
human
metapneumoviru
hmpv
rhinoviru
less
frequent
adenoviru
parainfluenza
influenza
coronaviru
recent
identifi
bocaviru
manag
bronchiol
primarili
support
concentr
major
complic
inadequ
feed
respiratori
distress
apnoea
fluid
either
enter
parenter
oxygen
mainstay
although
cpap
mechan
ventil
effect
respiratori
failur
role
bronchodil
corticosteroid
antivir
agent
physiotherapi
nebul
dnase
antibiot
nebul
hyperton
salin
administ
bronchodil
may
decreas
length
stay
hospit
prevent
strategi
rsv
immunoglobulin
antirsv
monoclon
antibodi
palivuzimab
decreas
diseas
sever
need
hospit
although
controversi
benefit
